Pfiz­er heads to the FDA with an ear­ly lead over ri­vals in the $10B RSV vac­cine mar­ket

The 50-year race to de­vel­op an RSV vac­cine turned a cor­ner on Thurs­day with Pfiz­er un­veil­ing promis­ing piv­otal da­ta for its bi­va­lent RSV vac­cine can­di­date …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER